[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100575173":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":39,"centralContacts":44,"locations":55,"responsibleParty":72,"collaborators":19,"id":75,"slug":76,"hasResults":77,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":19,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":83,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":19,"studyType":89,"phases":90,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":57,"whyStopped":19,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"South Valley University","OTHER",[8,15,20],{"label":9,"type":10,"description":11,"interventionNames":12},"baricitinib","ACTIVE_COMPARATOR","group A, vitiligo patients will receive oral baricitinib plus narrow band ultraviolet rays B phototherapy for 3 to 6 months and serum s100B will be measured before the start of the treatment and after three months of the treatment.",[13,14],"Drug: Baricitinib","Radiation: Narrow Band UVB Treatment",{"label":16,"type":17,"description":18,"interventionNames":19},"control","NO_INTERVENTION","healthy matched controls for them serum s100B will be measured",null,{"label":21,"type":10,"description":22,"interventionNames":23},"oral mini pulse","vitiligo patients will recieve oral mini pulse therapy plus phototherapy for three to six months ,serum s100B will be measured before and three months after start of the treatment.",[24,14],"Drug: oral mini pulse",[26,31,34],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":19},"DRUG","Baricitinib","oral baricitinib 4mg for adults and 2mg for children 10-16 years for group A",[9],{"type":27,"name":21,"description":32,"armGroupLabels":33,"otherNames":19},"pulse dose of oral dexamethasone 2.5mg for adults for two consecutive days per week and half the dose for children",[21],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":19},"RADIATION","Narrow Band UVB Treatment","narrowband ultraviolet rays B phototherapy two sessions per week",[9,21],[40],{"name":41,"affiliation":42,"role":43},"EMAN A OSMAN, bachelor","Qena university hospital, Qena faculty of medicine","PRINCIPAL_INVESTIGATOR",[45,51],{"name":46,"role":47,"phone":48,"phoneExt":49,"email":50},"Eman A Osman, bachelor","CONTACT","+20 1127052748","+20 1070265507","em.ea01127@gmail.com",{"name":52,"role":47,"phone":53,"phoneExt":19,"email":54},"Hassan mo farid, bachelor","+201040435051","dr.hassanfarid96@gmail.com",[56],{"facility":42,"status":57,"city":58,"state":19,"zip":19,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"RECRUITING","Qina","Egypt","EG",{"type":62,"coordinates":63},"Point",[64,65],32.72671,26.16418,{"lat":65,"lon":64},[68],{"name":69,"role":47,"phone":70,"phoneExt":19,"email":71},"ali m mohamed","+201001860635","Ali.moussa@svu.edu.eg",{"type":43,"investigatorFullName":73,"investigatorTitle":74,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Eman Ahmed Osman","resident doctor","100575173","phase-2-vitiligo-new-treatment-and-serum-s100b-100575173",false,"NCT06768840","Vitiligo, New Treatment and Serum s100B","Serum s100B in Generalized Vitiligo and Its Relation to Oral Baricitinib, Narrow Band Ultraviolet (B) Therapy","Inclusion Criteria:\n\n* active generalized vitiligo patients with body surface area involved \\>5% excluding hands and feet\n* no systemic treatment for vitiligo for the last 3 months or topical treatment received for the last 4 weeks.\n\nExclusion Criteria:\n\n* acrofacial, acral, segmental or mucosal vitiligo\n* patients on another immunosuppressive agent\n* patients have other skin conditions (psoriasis, SLE, alopecia areata) that would interfere with evaluations of the effect of study medication on vitiligo.\n* patients who suffered from systemic diseases affecting S100B (e.g. Subarachnoid hemorrhage, Alzheimer disease and inflammatory diseases) or from other dermatological diseases affecting S100B level (e.g. malignant melanoma)\n* Patients immunocompromised, uncontrolled arterial hypertension, clinically serious viral, bacterial, fungal, or parasitic infection, anemia, history of thromboembolic event, cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, lymphoproliferative disease, neurological, or neuropsychiatric disorders or any other serious and\u002For unstable illness.\n* Pregnancy and lactation.",true,"ALL","10 Years","75 Years",{"count":87,"type":88},50,"ESTIMATED","INTERVENTIONAL",[91,92],"PHASE2","PHASE3","vitiligo is an autoimmune depigmenting skin disorder characterized by milky white macules or patches, with 2% worldwide prevalence. Vitiligo has unexpected course that significantly influences on patient's quality of life and self-esteem.\n\nMultiple medications have been introduced for vitiligo treatment, in this study we work on one of systemic JAK inhibitors",[95],"Vitiligo, Generalized",[97,98,9,21,99,100],"vitiligo","jak inhibitor","dexamethasone","phototherapy","2025-01-06",{"date":103,"type":104},"2025-01-10","ACTUAL",{"date":106,"type":104},"2024-10-02",{"date":108,"type":88},"2025-10",{"name":5,"class":6},1]